Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Journeytcon Nov 04, 2023 11:36am
233 Views
Post# 35717400

RE:RE:RE:The call & mid afternoon update

RE:RE:RE:The call & mid afternoon update Fox I doubt ONC is looking for a deal now at least in earnest.   They don't know what they want.  I think they were ready to deal  coming off June but the Bracelet result caught them by surprise.  
It's easy to cut a deal.  It should take a minimum of two months of time.  Hire an investment firm,  send out notification of intent, structure a two page term sheet and list key info you seek in tender
Distribute the term sheet and give a months time for companies to prepare and put forward offers.  Collect, organize, clarify and rank offers. Negotiate with short list of companies.  Select company and workout final contract details and sign the agreement.
If this process isn't happening. It's because ONC is not ready. 
In the mean time.  If a company submits a great offer they'll take it.  And companies will be conducting due diligence in preparation.
The time will come for a deal after the Phase 3 breast cancer trial details are sorted out.  My guess is the breast cancer phase 3 trial is the critical path item for a deal in breast cancer, pancreatic cancer etc.
<< Previous
Bullboard Posts
Next >>